We build partnerships with likeminded innovators to improve patient healthcare worldwide. Thanks to a defined therapeutic focus and a straightforward initial assessment process, we are able to react rapidly, moving negotiations forward in a short time.
Our experience allows us to offer significant added value to companies who want to partner with a committed global company, capable of successfully marketing its assets and willing to give the right priority to in-licensed projects.
Our business model is a successful combination of Science, R&D and corporate development, where in-licensing will continue to be a key driver of future transformation for our company. Our most recent in-licensing deals (i.e. Sativex, Sitagliptin, Silodosin) illustrate our potential to establish alliances with companies ranging from biotech to Big Pharma.
In-Licensing in Therapeutic Areas.
We don't wait, we commit. That's why we are always looking for new in-licensing products that will help us to provide better healthcare solutions to fight skin diseases and MS Spasticity. Our main therapeutic areas are:
- Dermatology, with a focus on non-melanoma skin cancer, atopic dermatitis/eczema, psoriasis, acne, onychomycosis and other related indications, at any stage of development.
- Multiple Sclerosis (MS), only for late stage projects.
The licensing process: Maximising values.
You + Almirall = A way to partner.
Find out how we partner with other companies, from identifying initial opportunities to alliance management:
CORPORATE DEVELOPMENT (CD)
Identifies partnering oportunities and starts internal evaluation
Drives the negociation process, building value throgh the deal-making process
collaboration between partners